Archive · 25 May 2025
Bharat Biotech's Hillchol Vaccine Completes Phase III Trials
Imagine a tiny army fighting a nasty tummy bug called cholera.
Bharat Biotech made a new weapon, a vaccine called Hillchol, to help.
They tested it on many people, from babies to adults, and it worked really well!
The vaccine helps your body make soldiers (antibodies) to fight the bug.
It was safe, and the tests showed it's just as good as the other vaccines.
The company can now make lots of this vaccine to help people around the world, especially in places where cholera is a big problem.
This new vaccine can help prevent many people from getting very sick.
Bharat Biotech's Hillchol oral cholera vaccine successfully completed Phase III trials.
The vaccine demonstrated efficacy against both Ogawa and Inaba serotypes.
Trials showed over a four-fold rise in vibriocidal antibodies.
The vaccine was found non-inferior to existing licensed vaccines with a strong safety profile.
Bharat Biotech can produce 200 million doses annually, easing global shortages.
- Who
- Bharat Biotech, patients in India
- What
- Bharat Biotech's Hillchol oral cholera vaccine completed Phase III trials.
- When
- Findings recently published.
- Where
- Trials conducted at 10 clinical sites in India.
- Why
- To evaluate the safety, immunogenicity, and efficacy of the vaccine.
- Location
- Hyderabad, India
- Product
- Hillchol, oral cholera vaccine
- Trial Phase
- Phase III clinical trials
- Immunogenicity
- Over 4-fold increase in vibriocidal antibodies
- Participants
- 1,800 individuals across 10 sites in India
- Production Capacity
- 200 million doses
- Global Cholera Impact
- 2.86 million cases & 95,000 deaths annually